We recently found that a new pathogenic chimeric simian-human immunodeficiency virus
(SHIV) elicited heterologous human immunodeficiency virus type-1 (HIV-1) neutralizing …

Global elimination of pediatric human immunodeficiency virus (HIV) infections will require
the development of novel immune-based approaches, and understanding infant immunity to …

Infants and children infected with human immunodeficiency virus (HIV)-1 have been shown
to develop neutralizing antibodies (nAbs) against heterologous HIV-1 strains, characteristic …

Simian-human immunodeficiency virus (SHIV) models for human immunodeficiency virus
(HIV) infection have been widely used in passive studies with HIV neutralizing antibodies …

Chimeric simian/human immunodeficiency viruses (SHIVs) are widely used in nonhuman
primate models to recapitulate human immunodeficiency virus (HIV) infection in humans, yet …

Transmission of HIV-1 to newborns and infants remains high, with 130,000 new infections in
2022 in resource poor settings. Half of HIV-infected newborns, if untreated, progress to …

Passive administration of HIV neutralizing antibodies (nAbs) can protect macaques from
hard-to-neutralize (tier 2) chimeric simian-human immunodeficiency virus (SHIV) challenge …

Broadly neutralizing antibodies (BnAbs) protect macaques from cell-free simian/human
immunodeficiency virus (SHIV) challenge, but their efficacy against cell-associated SHIV is …

In a primate model of postnatal virus transmission, we have previously shown that 1 h post-
exposure prophylaxis (PEP) with a triple combination of neutralizing monoclonal antibodies …

Mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) continues to
cause new pediatric cases of infection through breastfeeding, a setting where it is not always …